Biocryst Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering, developing, and commercializing novel, orally administered, small-molecule therapeutics for rare and orphan diseases. The company's primary commercial driver is ORLADEYO (berotralstat), an oral, once-daily plasma kallikrein inhibitor approved for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients. BioCryst also markets RAPIVAB (peramivir injection), an intravenous neuraminidase inhibitor for acute uncomplicated influenza. Strategically, the company has expanded its HAE franchise through the acquisition of Astria Therapeutics, adding navenibart (a Phase 3 monoclonal antibody) to its pipeline, and has divested its European ORLADEYO business to optimize commercial focus.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding leadership in hereditary angioedema (HAE) by offering a comprehensive ecosystem: ORLADEYO oral capsules for adults, ORLADEYO oral pellets for pediatric patients (ages 2 to <12), and the newly acquired navenibart long-acting injectable prophylactic.
Expected impact: Aims to capture significant market share from existing injectable therapies and drive combined HAE franchise revenues to $1 billion by 2029 and over $1.8 billion by 2033.
Streamlining operations and maximizing commercial efficiency by divesting European commercial rights to Neopharmed Gentili, allowing BioCryst to focus its direct commercial infrastructure entirely on the high-value U.S. market.
Expected impact: Significantly reduces international operating overhead, improves non-GAAP operating margins, and strengthens the balance sheet with non-dilutive upfront capital.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To integrate Astria's late-stage plasma kallikrein inhibitor, navenibart (Phase 3), and early-stage atopic dermatitis asset, STAR-0310, into BioCryst's rare disease portfolio, establishing a dual oral/injectable HAE franchise.
Financial impact: Financed via cash on hand, a Blackstone credit facility draw of $396.6 million, and the issuance of 37.3 million common shares. Resulted in a one-time non-cash GAAP charge of $697.8 million for acquired in-process R&D in Q1 2026.
Strategic Partnerships
Grants Neopharmed Gentili exclusive rights to commercialize navenibart in Europe, leveraging their established regional infrastructure while allowing BioCryst to focus direct commercial efforts on the U.S.
Terms: BioCryst received $70 million upfront and is eligible for up to $275 million in future regulatory and sales milestones, plus tiered royalties on European net sales ranging from 18% to 30%.
Provides non-dilutive capital to fund strategic acquisitions (such as Astria Therapeutics) and support late-stage clinical development pipelines.
Terms: BioCryst drew approximately $396.6 million (net of expenses) from a senior credit facility with funds managed by Blackstone to finance the cash portion of the Astria acquisition.